Desensitization in Crossmatch-positive Kidney Transplant Candidates.
Journal
Transplantation
ISSN: 1534-6080
Titre abrégé: Transplantation
Pays: United States
ID NLM: 0132144
Informations de publication
Date de publication:
01 02 2023
01 02 2023
Historique:
pubmed:
9
8
2022
medline:
28
1
2023
entrez:
8
8
2022
Statut:
ppublish
Résumé
Access to kidney transplantation is limited by HLA-specific sensitization. Desensitization strategies enable crossmatch-positive kidney transplantation. In this review, we describe clinical experience gained over the last 20 y using desensitization strategies before kidney transplantation and describe the different tools used (both drugs and apheresis options), including IVIg, rituximab, apheresis techniques, interleukin-6 interference, proteasome inhibition, enzymatic degradation of HLA antibodies, complement inhibition, and B cytokine interference. Although access to transplantation for highly sensitized kidney transplantation candidates has been vastly improved by desensitization strategies, it remains, however, limited by the recurrence of HLA antibodies after transplantation and the occurrence of antibody-mediated rejection.
Identifiants
pubmed: 35939390
doi: 10.1097/TP.0000000000004279
pii: 00007890-202302000-00016
doi:
Substances chimiques
Rituximab
4F4X42SYQ6
Antibodies
0
Immunoglobulins, Intravenous
0
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
351-360Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
L.R. has received honoraria from BMS and Hansa Bopharma. The other authors declare no conflicts of interest.
Références
Lefaucheur C, Loupy A. Antibody-mediated rejection of solid-organ allografts. N Engl J Med. 2018;379:1150–1160.
Pruthi R, Hilton R, Pankhurst L, et al. UK Renal Registry 16 th annual report: chapter 4 demography of patients waitlisted for renal transplantation in the UK: national and centre-specific analyses. Nephron Clin Pract. 2013;125:81–98.
Vincenti F, Rostaing L, Grinyo J, et al. Belatacept and long-term outcomes in kidney transplantation. N Engl J Med. 2016;374: 333–343.
Chong AS. New insights into the development of B cell responses: implications for solid organ transplantation. Hum Immunol. 2019;80: 378–384.
Chong AS, Sciammas R. Memory B cells in transplantation. Transplantation. 2015;99:21–28.
Amanna IJ, Carlson NE, Slifka MK. Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med. 2007;357:1903–1915.
Amanna IJ, Slifka MK. Mechanisms that determine plasma cell lifespan and the duration of humoral immunity. Immunol Rev. 2010;236:125–138.
Slocombe T, Brown S, Miles K, et al. Plasma cell homeostasis: the effects of chronic antigen stimulation and inflammation. J Immunol. 2013;191:3128–3138.
Roth K, Oehme L, Zehentmeier S, et al. Tracking plasma cell differentiation and survival. Cytometry A. 2014;85:15–24.
Moran I, Nguyen A, Khoo WH, et al. Memory B cells are reactivated in subcapsular proliferative foci of lymph nodes. Nat Commun. 2018;9:3372.
Zuccarino-Catania GV, Sadanand S, Weisel FJ, et al. CD80 and PD-L2 define functionally distinct memory B cell subsets that are independent of antibody isotype. Nat Immunol. 2014;15:631–637.
Shouval D, Shibolet O. Immunosuppression and HBV reactivation. Semin Liver Dis. 2013;33:167–177.
Burton AR, Maini MK. Human antiviral B cell responses: emerging lessons from hepatitis B and COVID-19. Immunol Rev. 2021;299:108–117.
Hammarlund E, Thomas A, Amanna IJ, et al. Plasma cell survival in the absence of B cell memory. Nat Commun. 2017;8:1781.
Kwun J, Burghuber C, Manook M, et al. Successful desensitization with proteasome inhibition and costimulation blockade in sensitized nonhuman primates. Blood Adv. 2017;1:2115–2119.
Chen J, Wang Q, Yin D, et al. Cutting edge: CTLA-4Ig inhibits memory B cell responses and promotes allograft survival in sensitized recipients. J Immunol. 2015;195:4069–4073.
Bray RA, Gebel HM, Townsend R, et al. Posttransplant reduction in preexisting donor-specific antibody levels after belatacept- versus cyclosporine-based immunosuppression: post hoc analyses of BENEFIT and BENEFIT-EXT. Am J Transplant. 2018;18:1774–1782.
Bray RA, Gebel HM, Townsend R, et al. De novo donor-specific antibodies in belatacept-treated vs cyclosporine-treated kidney-transplant recipients: post hoc analyses of the randomized phase III BENEFIT and BENEFIT-EXT studies. Am J Transplant. 2018;18:1783–1789.
Chavarot N, Morel A, Leruez-Ville M, et al. Weak antibody response to three doses of mRNA vaccine in kidney transplant recipients treated with belatacept. Am J Transplant. 2021;21:4043–4051.
Ou MT, Boyarsky BJ, Chiang TPY, et al. Immunogenicity and reactogenicity after SARS-CoV-2 mRNA vaccination in kidney transplant recipients taking belatacept. Transplantation. 2021;105:2119–2123.
Meneghini M, Crespo E, Niemann M, et al. Donor/recipient HLA molecular mismatch scores predict primary humoral and cellular alloimmunity in kidney transplantation. Front Immunol. 2020;11:623276.
Bestard O, Meneghini M, Crespo E, et al. Preformed T cell alloimmunity and HLA eplet mismatch to guide immunosuppression minimization with tacrolimus monotherapy in kidney transplantation: results of the CELLIMIN trial. Am J Transplant. 2021;21:2833–2845.
Montgomery RA, Lonze BE, King KE, et al. Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med. 2011;365:318–326.
Orandi BJ, Montgomery RA, Segev DL. Kidney transplants from HLA-incompatible live donors and survival. N Engl J Med. 2016;375:288–289.
Manook M, Koeser L, Ahmed Z, et al. Post-listing survival for highly sensitised patients on the UK kidney transplant waiting list: a matched cohort analysis. Lancet. 2017;389:727–734.
Noble J, Metzger A, Daligault M, et al. Immortal time-bias-corrected survival of highly sensitized patients and HLA-desensitized kidney transplant recipients. Kidney Int Rep. 2021;6:2629–2638.
Gleiss A, Oberbauer R, Heinze G. An unjustified benefit: immortal time bias in the analysis of time-dependent events. Transpl Int. 2018;31:125–130.
Koo TY, Lee JH, Min SI, et al. Presence of a survival benefit of HLA-incompatible living donor kidney transplantation compared to waiting or HLA-compatible deceased donor kidney transplantation with a long waiting time. Kidney Int. 2021;100:206–214.
Jackson KR, Motter JD, Kernodle A, et al. How do highly sensitized patients get kidney transplants in the United States? Trends over the last decade. Am J Transplant. 2020;20:2101–2112.
Amrouche L, Aubert O, Suberbielle C, et al. Long-term outcomes of kidney transplantation in patients with high levels of preformed DSA: The Necker High-Risk Transplant Program. Transplantation. 2017;101:2440–2448.
Sapir-Pichhadze R, Tinckam KJ, Laupacis A, et al. Immune sensitization and mortality in wait-listed kidney transplant candidates. J Am Soc Nephrol. 2016;27:570–578.
Claas FH, Witvliet MD, Duquesnoy RJ, et al. The acceptable mismatch program as a fast tool for highly sensitized patients awaiting a cadaveric kidney transplantation: short waiting time and excellent graft outcome. Transplantation. 2004;78:190–193.
Glotz D, Antoine C, Julia P, et al. Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). Am J Transplant. 2002;2:758–760.
Jordan SC, Vo A, Bunnapradist S, et al. Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Transplantation. 2003;76:631–636.
Vo AA, Toyoda M, Peng A, et al. Effect of induction therapy protocols on transplant outcomes in crossmatch positive renal allograft recipients desensitized with IVIG. Am J Transplant. 2006;6:2384–2390.
Vo AA, Peng A, Toyoda M, et al. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation. 2010;89:1095–1102.
Vo AA, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med. 2008;359:242–251.
Vo AA, Wechsler EA, Wang J, et al. Analysis of subcutaneous (SQ) alemtuzumab induction therapy in highly sensitized patients desensitized with IVIG and rituximab. Am J Transplant. 2008;8:144–149.
Jordan SC, Tyan D, Stablein D, et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol. 2004;15:3256–3262.
Chauhan K, Mehta AA. Rituximab in kidney disease and transplant. Animal Model Exp Med. 2019;2:76–82.
Vo AA, Petrozzino J, Yeung K, et al. Efficacy, outcomes, and cost-effectiveness of desensitization using IVIG and rituximab. Transplantation. 2013;95:852–858.
Jackson AM, Kraus ES, Orandi BJ, et al. A closer look at rituximab induction on HLA antibody rebound following HLA-incompatible kidney transplantation. Kidney Int. 2015;87:409–416.
Vo AA, Choi J, Cisneros K, et al. Benefits of rituximab combined with intravenous immunoglobulin for desensitization in kidney transplant recipients. Transplantation. 2014;98:312–319.
Sethi S, Choi J, Toyoda M, et al. Desensitization: overcoming the immunologic barriers to transplantation. J Immunol Res. 2017;2017:6804678.
Redfield RR, Jordan SC, Busque S, et al. Safety, pharmacokinetics, and pharmacodynamic activity of obinutuzumab, a type 2 anti-CD20 monoclonal antibody for the desensitization of candidates for renal transplant. Am J Transplant. 2019;19:3035–3045.
Montgomery RA, Zachary AA, Racusen LC, et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation. 2000;70:887–895.
Schweitzer EJ, Wilson JS, Fernandez-Vina M, et al. A high panel-reactive antibody rescue protocol for cross-match-positive live donor kidney transplants. Transplantation. 2000;70:1531–1536.
Higgins RM, Bevan DJ, Carey BS, et al. Prevention of hyperacute rejection by removal of antibodies to HLA immediately before renal transplantation. Lancet. 1996;348:1208–1211.
Gloor JM, DeGoey SR, Pineda AA, et al. Overcoming a positive crossmatch in living-donor kidney transplantation. Am J Transplant. 2003;3:1017–1023.
Magee CC, Felgueiras J, Tinckam K, et al. Renal transplantation in patients with positive lymphocytotoxicity crossmatches: one center’s experience. Transplantation. 2008;86:96–103.
Thielke JJ, West-Thielke PM, Herren HL, et al. Living donor kidney transplantation across positive crossmatch: the University of Illinois at Chicago experience. Transplantation. 2009;87:268–273.
Jin MK, Cho JH, Kwon O, et al. Successful kidney transplantation after desensitization using plasmapheresis, low-dose intravenous immunoglobulin, and rituximab in highly sensitized patients: a single-center experience. Transplant Proc. 2012;44:200–203.
Pandey P, Setya D, Sinha VK, et al. Outcome of desensitization in human leukocyte antigen and ABO incompatible living donor kidney transplantation: single center experience of first 200 incompatible transplants. J Clin Apher. 2021;36:299–312.
Haririan A, Nogueira J, Kukuruga D, et al. Positive cross-match living donor kidney transplantation: longer-term outcomes. Am J Transplant. 2009;9:536–542.
Stegall MD, Gloor J, Winters JL, et al. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant. 2006;6:346–351.
Loupy A, Suberbielle-Boissel C, Zuber J, et al. Combined posttransplant prophylactic IVIg/anti-CD 20/plasmapheresis in kidney recipients with preformed donor-specific antibodies: a pilot study. Transplantation. 2010;89:1403–1410.
Niederhaus SV, Muth B, Lorentzen DF, et al. Luminex-based desensitization protocols: the University of Wisconsin initial experience. Transplantation. 2011;92:12–17.
Haas M, Böhmig GA, Leko-Mohr Z, et al. Peri-operative immunoadsorption in sensitized renal transplant recipients. Nephrol Dial Transplant. 2002;17:1503–1508.
Lorenz M, Regele H, Schillinger M, et al. Peritransplant immunoadsorption: a strategy enabling transplantation in highly sensitized crossmatch-positive cadaveric kidney allograft recipients. Transplantation. 2005;79:696–701.
Marlu R, Bennani HN, Seyve L, et al. Effect of immunoadsorption alone or combined with membrane filtration on hemostasis parameters. J Clin Apher. 2020;35:444–452.
Jouve T, Marlu R, Naciri Bennani H, et al. Fibrinogen reconstitution after therapeutic apheresis: comparison of double-filtration plasmapheresis, plasma exchange, and immunoadsorption. J Clin Apher. 2021;36:574–583.
Marlu R, Naciri Bennani H, Seyve L, et al. Comparison of three modalities of plasmapheresis on coagulation: centrifugal, single-membrane filtration, and double-filtration plasmapheresis. J Clin Apher. 2021;36:408–419.
Noble J, Metzger A, Naciri Bennani H, et al. Apheresis efficacy and tolerance in the setting of HLA-incompatible kidney transplantation. J Clin Med. 2021;10:1316.
Jambon F, Merville P, Guidicelli G, et al. Efficacy of plasmapheresis and semi-selective immunoadsorption for removal of anti-HLA antibodies. J Clin Apher. 2021;36:291–298.
Vo AA, Choi J, Kim I, et al. A phase I/II trial of the interleukin-6 receptor-specific humanized monoclonal (tocilizumab) + intravenous immunoglobulin in difficult to desensitize patients. Transplantation. 2015;99:2356–2363.
Daligault M, Bardy B, Noble J, et al. Marginal impact of tocilizumab monotherapy on anti-HLA alloantibodies in highly sensitized kidney transplant candidates. Transplant Direct. 2021;7:e690.
Jouve T, Laheurte C, Noble J, et al. Immune responses following tocilizumab therapy to desensitize HLA-sensitized kidney transplant candidates. Am J Transplant. 2022;22:71–84.
Choi J, Aubert O, Vo A, et al. Assessment of tocilizumab (anti-interleukin-6 receptor monoclonal) as a potential treatment for chronic antibody-mediated rejection and transplant glomerulopathy in HLA-sensitized renal allograft recipients. Am J Transplant. 2017;17:2381–2389.
Doberer K, Duerr M, Halloran PF, et al. A randomized clinical trial of anti-IL-6 antibody clazakizumab in late antibody-mediated kidney transplant rejection. J Am Soc Nephrol. 2021;32:708–722.
Vo AA, Huang E, Ammerman N, et al. Clazakizumab for desensitization in highly sensitized patients awaiting transplantation. Am J Transplant. 2022;22:1133–1144.
Lorant T, Bengtsson M, Eich T, et al. Safety, immunogenicity, pharmacokinetics, and efficacy of degradation of anti-HLA antibodies by IdeS (imlifidase) in chronic kidney disease patients. Am J Transplant. 2018;18:2752–2762.
Jordan SC, Lorant T, Choi J. IgG endopeptidase in highly sensitized patients undergoing transplantation. N Engl J Med. 2017;377:1693–1694.
Jordan SC, Legendre C, Desai NM, et al. Imlifidase desensitization in crossmatch-positive, highly sensitized kidney transplant recipients: results of an International Phase 2 Trial (Highdes). Transplantation. 2021;105:1808–1817.
Lonze BE, Tatapudi VS, Weldon EP, et al. IdeS (Imlifidase): a novel agent that cleaves human IgG and permits successful kidney transplantation across high-strength donor-specific antibody. Ann Surg. 2018;268:488–496.
Kjellman C, Maldonado AQ, Sjöholm K, et al. Outcomes at 3 years posttransplant in imlifidase-desensitized kidney transplant patients. Am J Transplant. 2021;21:3907–3918.
Woodle ES, Shields AR, Ejaz NS, et al. Prospective iterative trial of proteasome inhibitor-based desensitization. Am J Transplant. 2015;15:101–118.
Moreno Gonzales MA, Gandhi MJ, Schinstock CA, et al. 32 doses of bortezomib for desensitization is not well tolerated and is associated with only modest reductions in anti-HLA antibody. Transplantation. 2017;101:1222–1227.
Tremblay S, Driscoll JJ, Rike-Shields A, et al. A prospective, iterative, adaptive trial of carfilzomib-based desensitization. Am J Transplant. 2020;20:411–421.
Sriwattanakomen R, Xu Q, Demehin M, et al. Impact of carfilzomib-based desensitization on heart transplantation of sensitized candidates. J Heart Lung Transplant. 2021;40:595–603.
Vo AA, Zeevi A, Choi J, et al. A phase I/II placebo-controlled trial of C1-inhibitor for prevention of antibody-mediated rejection in HLA sensitized patients. Transplantation. 2015;99:299–308.
Orandi BJ, Zachary AA, Dagher NN, et al. Eculizumab and splenectomy as salvage therapy for severe antibody-mediated rejection after HLA-incompatible kidney transplantation. Transplantation. 2014;98:857–863.
Bentall A, Tyan DB, Sequeira F, et al. Antibody-mediated rejection despite inhibition of terminal complement. Transpl Int. 2014;27:1235–1243.
Glotz D, Russ G, Rostaing L, et al.; C10-002 Study Group. Safety and efficacy of eculizumab for the prevention of antibody-mediated rejection after deceased-donor kidney transplantation in patients with preformed donor-specific antibodies. Am J Transplant. 2019;19:2865–2875.
Marks WH, Mamode N, Montgomery RA, et al.; C10-001 Study Group. Safety and efficacy of eculizumab in the prevention of antibody-mediated rejection in living-donor kidney transplant recipients requiring desensitization therapy: a randomized trial. Am J Transplant. 2019;19:2876–2888.
Clatworthy MR. B-cell regulation and its application to transplantation. Transpl Int. 2014;27:117–128.
Agarwal D, Luning Prak ET, Bharani T, et al. BLyS neutralization results in selective anti-HLA alloantibody depletion without successful desensitization. Transpl Immunol. 2021;69:101465.
Bath NM, Ding X, Verhoven BM, et al. Autoantibody production significantly decreased with APRIL/BLyS blockade in murine chronic rejection kidney transplant model. PLoS One. 2019;14:e0223889.
Wilson NA, Bath NM, Verhoven BM, et al. APRIL/BLyS blockade reduces donor-specific antibodies in allosensitized mice. Transplantation. 2019;103:1372–1384.
Joher N, Matignon M, Grimbert P. HLA desensitization in solid organ transplantation: anti-CD38 to across the immunological barriers. Front Immunol. 2021;12:688301.
Kwun J, Matignon M, Manook M, et al. Daratumumab in sensitized kidney transplantation: potentials and limitations of experimental and clinical use. J Am Soc Nephrol. 2019;30:1206–1219.
Burghuber CK, Manook M, Ezekian B, et al. Dual targeting: combining costimulation blockade and bortezomib to permit kidney transplantation in sensitized recipients. Am J Transplant. 2019;19:724–736.
Guiteras J, De Ramon L, Crespo E, et al. Dual and opposite costimulatory targeting with a novel human fusion recombinant protein effectively prevents renal warm ischemia reperfusion injury and allograft rejection in murine models. Int J Mol Sci. 2021;22:1216.
Alishetti S, Farr M, Jennings D, et al. Desensitizing highly sensitized heart transplant candidates with the combination of belatacept and proteasome inhibition. Am J Transplant. 2020;20:3620–3630.
Jain D, Rajab A, Young JS, et al. Reversing donor-specific antibody responses and antibody-mediated rejection with bortezomib and belatacept in mice and kidney transplant recipients. Am J Transplant. 2020;20:2675–2685.